Filter
46
Featured
7
4
Language
Document type
19
13
7
3
1
1
1
1
Countries / Regions
5
3
2
1
Authors & Publishers
Publication Years
Category
7
3
1
1
Toolboxes
16
14
8
5
4
4
3
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
EACS produces Guidelines for the management of people living with HIV in Europe. The English version is regularly updated by the guidelines panels with major revision every other year and minor revisions in the years in between. Guidelines are published in the autumn and translated into additional l
...
Pregnancy often results in exclusion from clinical trials of antiretroviral (ARV) drugs, resulting in limited data on pharmacokinetics (PK), drug safety, and the efficacy of new ARV drugs in pregnancy and lactation. However, pregnancy, lactation, or the potential for pregnancy should not preclude th
...
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex G Abstract
WHO guideline on HIV service delivery
recommended
Updated guidance on the integration of diabetes, hypertension and mental health services, and interventions to support adherence to antiretroviral therapy. The guideline offers practical implementation guidance for countries and key stakeholders as well as outlining key research gaps. As life expec
...
Topics in Antiviral Medicine, March 4, 2025
СТАНДАРТ МЕДИЧНОЇ ДОПОМОГИ.
These clinical guidelines, released by the Ukraine Ministry of Health in 2025, include the latest recommendations for HIV services, including oral PrEP and injectable cabotegravir (CAB) for PrEP.
WHO updated recommendations on HIV clinical management: recommendations for a public health approach
recommended
This document provides an overview of the updated World Health Organization recommendations for HIV clinical management, which focus on optimizing antiretroviral therapy, preventing vertical transmission, and enhancing tuberculosis prevention among individuals with HIV. These updates are intended to
...
Questions and answers. A key priority is preventing the interruption of current HIV treatment and prevention medicines. This Q&A outlines advice when this is not possible. Available in Arabic, Chinese, English, French, Portuguese, Russian and Spanish
These 2025 guidelines respond to the need for better approaches to identify advanced HIV disease, improve the poor outcomes of people living with HIV being discharged from hospital and provide updated guidance for treatment for Kaposi’s sarcoma through evidence-informed recommendations. The public
...
About six in ten adolescents 10-19 years of age living with HIV are on antiretroviral medications
Slightly more than half of children under 15 years of age living with HIV are on antiretroviral medications
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations. The guidelines were updated to comply with Executive Orders. You can download the full guidelines, charts and recommendations
Nature communications, 16, 906 (2025). https://doi.org/10.1038/s41467-025-56116-1
Recent suspensions and reductions in official development assistance (ODA) have posed significant challenges to HIV programme continuity in several countries. These funding disruptions have impacted people living with HIV and other vulnerable populations
who rely on these essential services, like a
...
Modelling shows that it will be essential to complement lenacapavir with additional prevention options, testing and treatment. See “Meeting reports” at https://www.unaids.org/en/resources/publications/all for a description of models and tools to estimate potential impact and quantifications requ
...
Demographic and socioeconomic data Progress towards HIV testing and treatment cascade targets by 2025 (2023) Health sector cascade (2023) Estimated number of people newly infected with HIV
AIDS 2024, 38:1579–1588. Treatment interruptions are a barrier to successful antiretroviral therapy (ART). 'Fresh start messages', which leverage significant days on the calendar (e.g., new year, public holiday) in order to prompt action, have the potential to encourage people with HIV (PWH) to re
...
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment.
CDC leads an international surveillance effort to estimate the occurrence of HIV drug resistance among people with HIV who are taking dolutegravir (DTG)-based treatments. This surveillance effort utilizes Cyclical Acquired HIV Drug Resistance Surveillance (CADRE), a laboratory-based HIV drug resista
...
